High levels of circulating GM-CSF+CD4+ T cells are predictive of poor outcomes in sepsis patients: a prospective cohort study

Cellular and Molecular Immunology

Volumn 16, Issue 6, 2019, Pages 602-610

  Huang, Huihuang ^a   Wang, Siyu ^a   Jiang, Tianjun ^a   Fan, Rong ^a   Zhang, Zheng ^a   Mu, Jinsong ^a   Li, Ke ^a   Wang, Yonggang ^a   Jin, Lei ^a   Lin, Fang ^a   Xia, Jie ^a   Sun, Lijian ^a   Xu, Biao ^a   Ji, Chengcheng ^a   Chen, Jing ^b   Chang, Juan ^c   Tu, Bo ^a   Song, Bing ^a   Zhang, Chao ^a   Wang, Fu Sheng ^a   Xu, Ruonan ^a   more..

^a BEIJING 302 HOSPITAL   (China)

^b THIRD MILITARY MEDICAL UNIVERSITY   (China)

^c CHINESE PLA GENERAL HOSPITAL   (China)

Author keywords

CD4+ T cells; GM CSF; sepsis; SIRS

Indexed keywords

COMPLEMENT COMPONENT C3A RECEPTOR; COMPLEMENT RECEPTOR; GAMMA INTERFERON; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR ANTIBODY; INTERLEUKIN 1BETA; INTERLEUKIN 6; INTERLEUKIN 8; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CD4+ T LYMPHOCYTE; CLINICAL OUTCOME; COHORT ANALYSIS; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOKINE RELEASE; DISEASE COURSE; DISEASE SEVERITY; FEMALE; HUMAN; IN VITRO STUDY; MAJOR CLINICAL STUDY; MALE; MORTALITY; NEUTROPHIL; PHENOTYPE; PREDICTIVE VALUE; PROGNOSIS; PROSPECTIVE STUDY; PROTEIN EXPRESSION; RECEIVER OPERATING CHARACTERISTIC; SEPSIS; SYSTEMIC INFLAMMATORY RESPONSE SYNDROME; UPREGULATION; IMMUNOLOGY; LUNG; LYMPHOCYTE COUNT; METABOLISM; MIDDLE AGED; PATHOLOGY; SURVIVAL ANALYSIS;

ADULT; CD4-POSITIVE T-LYMPHOCYTES; COHORT STUDIES; FEMALE; GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR; HUMANS; LUNG; LYMPHOCYTE COUNT; MALE; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; PROGNOSIS; PROSPECTIVE STUDIES; SEPSIS; SURVIVAL ANALYSIS;

EID: 85055103518     PISSN: 16727681     EISSN: None     Source Type: Journal    
DOI: 10.1038/s41423-018-0164-2     Document Type: Article

References (24)

1. Levy, M. M. et al. SCCM/ESICM/ACCP/ATS/SI:2001SCCM/ESICM/ACCP/ATS/SIS International Sepsis Definitions Conference. Crit. Care Med. 31, 1250–1256 (2003).
2. Balk, R. A. Severe sepsis and septic shock. Crit. Care Clin. 16, 179–192 (2000).
3. Van Nieuwenhuijze, A. et al. GM-CSF as a therapeutic target in inflammatory diseases. Mol. Immunol. 56, 675–682 (2013).
4. Codarri, L. et al. RORγt derives production of the cytokine GM-CSF in helper T cells, which is essential for the effector phase of autoimmune neuroinflammation. Nat. Immunol. 12, 560–567 (2011).
5. EI-Behi, M. et al. The encephalitogenicity of TH17 cells is dependent on IL-1- and IL-23-induced production of the cytokine GM-CSF. Nat. Immunol. 12, 568–575 (2011).
6. Meisel, C. et al. Granulocyte–macrophage colony-stimulating factor to reverse sepsis-associated immunosuppression. Am. J. Respir. Crit. Care. Med. 180, 640–648 (2009).
7. Orozco, H. et al. Molgramostim (GM-CSF) associated with antibiotic treatment in nontraumatic abdominal sepsis. Arch. Surg. 141, 150–153 (2006).
8. Xu, R., Lin, F., Bao, C. & Wang, F. S. Mechanism of C5a-induced immunologic derangement in sepsis. Cell Mol. Immunol. 14, 792–793 (2017).
9. Burgess, A. W., Camakaris, J. & Metcalf, D. Purification and properties of colony-stimulating factor from mouse lung-conditioned medium. J. Biol. Chem. 252, 1998–2003 (1977).
10. Zhang, J. et al. A novel subset of helper T cells promotes immuneresponses by secreting GM-CSF. Cell Death Differ. 20, 1731–1741 (2013).
11. Rasouli, J. et al. Expression of GM-CSF in T cells is increased in multiple sclerosis and suppressed by IFN-β therapy. J. Immunol. 194, 5085–5093 (2015).
12. Luken, J. R., Barr, M. J., Chaplin, D. D., Chi, H. & Lanneganti, T. D. Inflammasome-derived IL-1β regulates the production of GM-CSF by CD4(+) T cells and γδT cells. J. Immunol. 188, 3107–3115 (2012).
13. Hazelzet, J. A. et al. Complement activation in relation to capillary leakage in children with septic shock and purpura. Infect. Immun. 66, 5350–5356 (1998).
14. Wu, M. C. et al. The receptor for complement component C3a mediates protection from intestinal ischemia-reperfusion injuries by inhibiting neutrophil mobilization. Proc. Natl. Acad. Sci. USA 110, 9439–9444 (2013).
15. Kovach, M. A. & Standiford, T. J. The function of neutrophils in sepsis. Curr. Opin. Infect. Dis. 25, 321–327 (2012).
16. Nelson, S. et al. A randomised controlled trial of filgrastim as an adjunct to antibiotics for treatment of hospitalised patients with community-acquired pneumonia. J. Infect. Dis. 178, 1075–1080 (1998).
17. Rauch, P. J. et al. Innate response activator B cells protect against microbial sepsis. Science 335, 597–601 (2012).
18. Souza-Fonseca-Guimaraes, F., Cavaillon, J. M. & Adib-Conquy, M. Bench-to-bedside review: natural killer cells in sepsis - guilty or not guilty? Crit. Care 17, 235–240 (2013).
19. Shao, R. et al. Monocyte programmed death ligand-1 expression after 3-4 days of sepsis is associated with risk stratification and mortality in septic patients: a prospective cohort study. Crit. Care 20, 124–134 (2016).
20. Drewry, A. M. et al. Comparison of monocyte human leukocyte antigen-DR expression and stimulated tumor necrosis factor alpha production as outcome predictors in severe sepsis: a prospective observational study. Crit. Care 20, 334–344 (2016).
21. Singer, M. & Deutschman, C. S. The third international consensus definitions for sepsis and septic shock (Sepsis-3). JAMA 315, 801–810 (2016).
22. Xu, R. et al. Complement 5a receptor –mediated neutrophil dysfunction is associated with a poor outcome in sepsis. Cell Mol Immunol. 13, 103–109 (2016).
23. Xu, R. et al. Low expression of CXCR1/2 on neutrophils predicts poor survival in patients with hepatitis B virus-related acutr-on-chronic liver failure. Sci. Rep. 6, 38714–38723 (2016).
24. Zhang, J. Y. et al. Interleukin-17–producing CD4(+) T cells increase with severity of liver damage in patients with chronic hepatitis B. Hepatology 51, 81–91 (2010).